ORPHA:418951
Undifferentiated carcinoma of esophagus
Also known as: Undifferentiated esophageal carcinoma
Publications
173
55.8th percentile
Trials
2
Interventional, condition-specific
Researchers
1,098
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, aggressive, malignant, epithelial carcinoma of the esophagus characterized, macroscopically, by an exophytic mass with central ulceration located on the esophagus and, histologically, by a sheet-like growth of neoplastic cells without significant glandular, squamous or neuroendocrine differentiation. Patients may present with dysphagia, long-standing history of gastroesophageal reflux, weight loss, anemia, abdominal or chest pain/pressure, dyspnea, and/or hematemesis. Presence or history of Barrett esophagus is frequently associated.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018481
- UMLS:C2188058
- NCIT:C27422
Additional Mondo synonyms (5)
esophageal undifferentiated carcinoma · esophagus undifferentiated carcinoma · oesophagus undifferentiated carcinoma · undifferentiated esophageal cancer · undifferentiated esophageal carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
173 matched papers (91 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
3
Drugs / clinical candidates · MONDO_0018481
- CARBOPLATIN·phase 2
- PACLITAXEL·phase 2
- PANITUMUMAB·phase 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
173
173 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
173 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
91 in the last 10 years · high confidence · 55.8th percentile (publications denominator)
Phrase hits: 173 · MeSH hits: 0
Who's working on it?
1,098
Distinct author names in 173 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang Y5 papers · 2026
CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory for Biomedical Effects of Nanomaterial and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, P. R. China.
Papers in Europe PMC - 02Yang Y5 papers · 2024
CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory for Biomedical Effects of Nanomaterial and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, P. R. China.
Papers in Europe PMC - 03Kim JH4 papers · 2021
Department of Gastroenterology, Inje University Busan Paik Hospital, Busan, Korea.
Papers in Europe PMC - 04Li EM4 papers · 2021
The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, Guangdong, 515041, P. R. China.
Papers in Europe PMC - 05
- 06Wang J4 papers · 2021
Jia Wang, Nan Wu, Qing-Feng Zheng, Shi Yan, Chao Lv, Shao-Lei Li, Yue Yang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery II, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing 100142, China.
Papers in Europe PMC - 07Xu J4 papers · 2024
Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, P. R. China.
Papers in Europe PMC - 08Xu LY4 papers · 2021
The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, Guangdong, 515041, P. R. China.
Papers in Europe PMC - 09Anderegg MCJ3 papers · 2026
Department of Surgery, Academic Medical Center, Amsterdam, the Netherlands.
Papers in Europe PMC - 10Gisbertz SS3 papers · 2026
Department of Surgery, Academic Medical Center, Amsterdam, the Netherlands.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; none in our sample are currently recruiting. 51 trials are registered for undifferentiated carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
high confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: undifferentiated carcinoma
51
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05925491·RECRUITING·Pembrolizumab in Locally Advanced Sinonasal Carcinoma
Not reviewed·Conditions: Sinonasal Undifferentiated Carcinoma·Matched via name phrase
- NCT06940180·RECRUITING·Toripalimab With Chemotherapy for Sinus Cancer
Not reviewed·Conditions: Sinonasal Cancer · Paranasal Sinus Neoplasms · Squamous Cell Carcinoma · Sinonasal Undifferentiated Carcinoma·Matched via name phrase
- NCT06814496·RECRUITING·Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Not reviewed·Conditions: Melanoma · Medullary Thyroid Cancer · Sinonasal Undifferentiated Carcinoma · Esthesioneuroblastoma·Matched via name phrase
- NCT05112601·RECRUITING·Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Not reviewed·Conditions: Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma·Matched via name phrase
- NCT06176989·RECRUITING·Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Not reviewed·Conditions: Metastatic Chondrosarcoma · Locally Advanced Chondrosarcoma · Metastatic Sinonasal Adenocarcinoma · Locally Advanced Sinonasal Adenocarcinoma·Matched via name phrase
- NCT05256225·RECRUITING·Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Not reviewed·Conditions: Endometrial Carcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Undifferentiated carcinoma of esophagus — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Undifferentiated carcinoma of esophagus" OR "Undifferentiated carcinoma of the esophagus" OR "Undifferentiated esophageal carcinoma" OR "esophageal undifferentiated carcinoma" OR "esophagus undifferentiated carcinoma" OR "oesophagus undifferentiated carcinoma" OR "undifferentiated esophageal cancer"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Undifferentiated carcinoma of esophagus" OR "Undifferentiated carcinoma of the esophagus" OR "Undifferentiated esophageal carcinoma" OR "esophageal undifferentiated carcinoma" OR "esophagus undifferentiated carcinoma" OR "oesophagus undifferentiated carcinoma" OR "undifferentiated esophageal cancer"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"undifferentiated carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:45:59.406Z
